OMERS ADMINISTRATION Corp Buys 15,125 Shares of Gilead Sciences, Inc. $GILD

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Gilead Sciences by 21.9%, now holding 84,308 shares worth approximately $9.45 million after acquiring 15,125 additional shares.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, with the ex-dividend date set for September 15, representing an annualized yield of 2.8%.
• Analysts have adjusted price targets for Gilead Sciences, with expectations ranging from $112.00 to $133.00 and a consensus rating of "Moderate Buy."

OMERS ADMINISTRATION Corp raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,308 shares of the biopharmaceutical company's stock after buying an additional 15,125 shares during the period. OMERS ADMINISTRATION Corp's holdings in Gilead Sciences were worth $9,447,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Redwood Financial Network Corp grew its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC raised its position in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after purchasing an additional 99 shares during the period. Peak Financial Advisors LLC raised its position in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after purchasing an additional 100 shares during the period. Perkins Coie Trust Co raised its position in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Trading Up 0.4%

Shares of GILD stock traded up $0.41 during mid-day trading on Monday, reaching $112.97. The stock had a trading volume of 4,629,720 shares, compared to its average volume of 6,308,101. The stock's 50-day moving average price is $113.01 and its two-hundred day moving average price is $109.66. Gilead Sciences, Inc. has a 52-week low of $77.74 and a 52-week high of $121.83. The firm has a market capitalization of $140.17 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 0.70 and a beta of 0.36. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the previous year, the company earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.